TY - JOUR
T1 - Using artificial intelligence-based models to predict the risk of mucormycosis among COVID-19 survivors
T2 - An experience from a public hospital in India
AU - Syed-Abdul, Shabbir
AU - Babu, A. Shoban
AU - Bellamkonda, Raja Shekhar
AU - Itumalla, Ramaiah
AU - Acharyulu, G. V.R.K.
AU - Krishnamurthy, Surya
AU - Ramana, Y. Venkat Santosh
AU - Mogilicharla, Naresh
AU - Malwade, Shwetambara
AU - Li, Yu Chuan
N1 - Funding Information:
This work is supported in part by Ministry of Science and Technology, Taiwan [Grant Nos. 108–2221-E-038–013, 110–2923-E-038 −001 -MY3]; Taipei Medical University, Taiwan [grant numbers 108–3805–009–110, 109–3800–020–400]; Ministry of Education, Taiwan [Grant No. 108–6604–002–400]; Wanfang hospital, Taiwan [Grant No. 106TMU-WFH-01–4].
Publisher Copyright:
© 2021
PY - 2022
Y1 - 2022
N2 - Introduction: India reported a severe public health challenge not only due to the COVID-19 outbreak but also the increasing number of associated mucormycosis cases since 2021.This study aimed at developing artificial intelligence based models to predict the risk of mucormycosis among the patients at the time of discharge from hospital. Methods: The dataset included of 1229 COVID-19 positive patients, and additional 214 inpatients, COVID-19 positive as well as infected with mucormycosis. We used logistic regression, decision tree and random forest and the extreme gradient boosting algorithm. All our models were evaluated with 5-fold validation to derive a reliable estimate of the model error. Results: The logistic regression, XGBoost and random forest performed equally well with AUROC 95.0, 94.0, and 94.0 respectively. The best accuracy and precision (PPV) were 0.91 ± 0.026 and 0.67 ± 0.0526, respectively achieved by XGBoost, followed by logistic regression. This study also determined top five variables namely obesity, anosmia, de novo diabetes, myalgia, and nasal discharge, which showed positive impact towards the risk of mucormycosis. Conclusion: The developed model has the potential to predict the patients at high risk and thus, consequently initiating preventive care or aiding in early detection of mucormycosis infection. Thus, this study, holds potential for early treatment and better management of patients suffering from COVID-19 associated mucormycosis.
AB - Introduction: India reported a severe public health challenge not only due to the COVID-19 outbreak but also the increasing number of associated mucormycosis cases since 2021.This study aimed at developing artificial intelligence based models to predict the risk of mucormycosis among the patients at the time of discharge from hospital. Methods: The dataset included of 1229 COVID-19 positive patients, and additional 214 inpatients, COVID-19 positive as well as infected with mucormycosis. We used logistic regression, decision tree and random forest and the extreme gradient boosting algorithm. All our models were evaluated with 5-fold validation to derive a reliable estimate of the model error. Results: The logistic regression, XGBoost and random forest performed equally well with AUROC 95.0, 94.0, and 94.0 respectively. The best accuracy and precision (PPV) were 0.91 ± 0.026 and 0.67 ± 0.0526, respectively achieved by XGBoost, followed by logistic regression. This study also determined top five variables namely obesity, anosmia, de novo diabetes, myalgia, and nasal discharge, which showed positive impact towards the risk of mucormycosis. Conclusion: The developed model has the potential to predict the patients at high risk and thus, consequently initiating preventive care or aiding in early detection of mucormycosis infection. Thus, this study, holds potential for early treatment and better management of patients suffering from COVID-19 associated mucormycosis.
KW - Artificial intelligence
KW - Coronavirus
KW - COVID-19
KW - Fungal infection
KW - India
KW - Mucormycosis
UR - http://www.scopus.com/inward/record.url?scp=85122181553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122181553&partnerID=8YFLogxK
U2 - 10.1016/j.jinf.2021.12.016
DO - 10.1016/j.jinf.2021.12.016
M3 - Article
AN - SCOPUS:85122181553
SN - 0163-4453
VL - 84
SP - 351
EP - 354
JO - Journal of Infection
JF - Journal of Infection
IS - 3
ER -